SCHEMBL2269578

SCHEMBL2269578

CC(=O)N(Cl)c1ccc2c(c1NC(=O)c1ccco1)C(=O)c1ccccc1C2=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
TP53 P04637 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.40
MAPK14 Q16539 1/20 0.40
LMNA P02545 2/20 0.40
SERPINE1 P05121 1/20 0.39
MAPK1 P28482 2/20 0.39
MAPK10 P53779 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MMP14 P50281 1/20 0.39
GRM1 Q13255 1/20 0.39
KMT2A Q03164 1/20 0.38
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267254 0.83 KMT2A (0.42) RAB9ASMN1; SMN2GAAMAPTLMNA
SCHEMBL2272381 0.83 ACE2 (0.47) SMN1; SMN2TSHRMAPTLMNAMAPK1
SCHEMBL2274863 0.81 ALDH1A1 (0.55) SMN1; SMN2GAAMAPTLMNAMAPK1
SCHEMBL2273092 0.81 ALDH1A1 (0.46) RAB9ATP53SMN1; SMN2TSHRMAPT
SCHEMBL2269186 0.81 ALDH1A1 (0.43) SMN1; SMN2GAAMAPTMAPK14LMNA
SCHEMBL2274343 0.81 ALDH1A1 (0.46) SMN1; SMN2MAPTMAPK1KDM4EALDH1A1
SCHEMBL2269057 0.81 ALDH1A1 (0.41) RAB9ATP53SMN1; SMN2TSHRMAPT
SCHEMBL2268881 0.80 PTPRC (0.47) RAB9ATP53SMN1; SMN2GAAMAPT
SCHEMBL2274384 0.80 MAPT (0.44) RAB9ATP53SMN1; SMN2TSHRMAPT
SCHEMBL2270337 0.79 HPGD (0.46) RAB9ASMN1; SMN2MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US claimed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US claimed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA1, ANXA5, ANXA2 RAB9A 1068/4885TP53 272/4885SMN1; SMN2 3794/4885
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA5, ANXA1, HCCS RAB9A 1294/4885TP53 229/4885SMN1; SMN2 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.